These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 37781611)

  • 1. Polymorphic Structure Determination of the Macrocyclic Drug Paritaprevir by MicroED.
    Bu G; Danelius E; Wieske LH; Gonen T
    bioRxiv; 2023 Sep; ():. PubMed ID: 37781611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphic Structure Determination of the Macrocyclic Drug Paritaprevir by MicroED.
    Bu G; Danelius E; Wieske LHE; Gonen T
    Adv Biol (Weinh); 2024 May; 8(5):e2300570. PubMed ID: 38381052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring of paritaprevir and glecaprevir resistance due to A156T mutation of HCV NS3/4A protease: molecular dynamics simulation study.
    Boonma T; Nutho B; Darai N; Rungrotmongkol T; Nunthaboot N
    J Biomol Struct Dyn; 2022 Aug; 40(12):5283-5294. PubMed ID: 33430709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating the role of macrocycles in the susceptibility of hepatitis C virus NS3/4A protease inhibitors to drug resistance.
    Ali A; Aydin C; Gildemeister R; Romano KP; Cao H; Ozen A; Soumana D; Newton A; Petropoulos CJ; Huang W; Schiffer CA
    ACS Chem Biol; 2013 Jul; 8(7):1469-78. PubMed ID: 23594083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding of the drug resistance mechanism of hepatitis C virus NS3/4A to paritaprevir due to D168N/Y mutations: A molecular dynamics simulation perspective.
    Boonma T; Nutho B; Rungrotmongkol T; Nunthaboot N
    Comput Biol Chem; 2019 Dec; 83():107154. PubMed ID: 31751885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular docking investigation of the binding interactions of macrocyclic inhibitors with HCV NS3 protease and its mutants (R155K, D168A and A156V).
    Ezat AA; El-Bialy NS; Mostafa HI; Ibrahim MA
    Protein J; 2014 Feb; 33(1):32-47. PubMed ID: 24374429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel potent hepatitis C virus NS3 serine protease inhibitors derived from proline-based macrocycles.
    Chen KX; Njoroge FG; Arasappan A; Venkatraman S; Vibulbhan B; Yang W; Parekh TN; Pichardo J; Prongay A; Cheng KC; Butkiewicz N; Yao N; Madison V; Girijavallabhan V
    J Med Chem; 2006 Feb; 49(3):995-1005. PubMed ID: 16451065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In silico identification and evaluation of leads for the simultaneous inhibition of protease and helicase activities of HCV NS3/4A protease using complex based pharmacophore mapping and virtual screening.
    Wadood A; Riaz M; Uddin R; Ul-Haq Z
    PLoS One; 2014; 9(2):e89109. PubMed ID: 24551230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of non-macrocyclic small molecule inhibitors against the NS3/4A serine protease of hepatitis C virus through in silico screening.
    Chaudhuri R; Lee H; Truong L; Torres J; Patel K; Johnson ME
    J Chem Inf Model; 2012 Aug; 52(8):2245-56. PubMed ID: 22697413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Molecular recognition mechanism and motion of HCV NS3/4A protease with Faldaprevir analogue].
    Liang L; Hu J; Du W; Zuo K; Liu W; Gou X
    Sheng Wu Gong Cheng Xue Bao; 2016 May; 32(5):669-682. PubMed ID: 29019204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A macrocyclic HCV NS3/4A protease inhibitor interacts with protease and helicase residues in the complex with its full-length target.
    Schiering N; D'Arcy A; Villard F; Simic O; Kamke M; Monnet G; Hassiepen U; Svergun DI; Pulfer R; Eder J; Raman P; Bodendorf U
    Proc Natl Acad Sci U S A; 2011 Dec; 108(52):21052-6. PubMed ID: 22160684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Macrocyclic Hepatitis C Virus NS3/4A Protease Inhibitors: An Overview of Medicinal Chemistry.
    Pillaiyar T; Namasivayam V; Manickam M
    Curr Med Chem; 2016; 23(29):3404-3447. PubMed ID: 27160539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroED as a powerful tool for structure determination of macrocyclic drug compounds directly from their powder formulations.
    Danelius E; Bu G; Wieske H; Gonen T
    bioRxiv; 2023 Aug; ():. PubMed ID: 37577574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 3D structural model and dynamics of hepatitis C virus NS3/4A protease (genotype 4a, strain ED43) suggest conformational instability of the catalytic triad: implications in catalysis and drug resistivity.
    Rimmert B; Sabet S; Ackad E; Yousef MS
    J Biomol Struct Dyn; 2014; 32(6):950-8. PubMed ID: 23768174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of interactions between the hepatitis C virus NS3/4A and sulfonamidobenzamide based molecules using molecular docking, molecular dynamics simulations and binding free energy calculations.
    Ren J; Vaid TM; Lee H; Ojeda I; Johnson ME
    J Comput Aided Mol Des; 2023 Jan; 37(1):53-65. PubMed ID: 36427108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroED as a Powerful Tool for Structure Determination of Macrocyclic Drug Compounds Directly from Their Powder Formulations.
    Danelius E; Bu G; Wieske LHE; Gonen T
    ACS Chem Biol; 2023 Dec; 18(12):2582-2589. PubMed ID: 37944119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of novel small molecule inhibitors against the NS3/4A protease of hepatitis C virus genotype 4a.
    El-Sayed SM; Ali MAM; El-Gendy BEM; Dandash SS; Issac Y; Saad R; Azab MM; Mohamed MR
    Curr Pharm Des; 2018; 24(37):4484-4491. PubMed ID: 30501598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The design of a potent inhibitor of the hepatitis C virus NS3 protease: BILN 2061--from the NMR tube to the clinic.
    Tsantrizos YS
    Biopolymers; 2004; 76(4):309-23. PubMed ID: 15386268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular docking study of P4-Benzoxaborolesubstituted ligands as inhibitors of HCV NS3/4A protease.
    Wadood A; Riaz M; Jamal SB; Shah M; Lodhi MA
    Bioinformation; 2013; 9(6):309-14. PubMed ID: 23559750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct Conformations of Mirabegron Determined by MicroED.
    Lin J; Unge J; Gonen T
    bioRxiv; 2023 Jun; ():. PubMed ID: 37425799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.